Profil De L’asthmatique Admis Au Centre Hospitalier National Universitaire De Fann (CHNU) A Dakar (Senegal)

Au Sénégal, la prévalence de l’asthme n’est pas encore évaluée. Les caractéristiques sociodémographiques, épidémiologiques et la provenance des patients asthmatiques consultés au Centre Hospitalier National Universitaire (CHNU) de Fann demeurent peu connues. Cet article contribue à la connaissance du profil des patients asthmatiques admis au CHNU. Il s’est agi d’une étude rétrospective, prospective et transversale à avisée analytique associant l’approche quantitative et qualitative qui s’est déroulée de janvier 1999 à août 2017 à la clinique de pneumologie du CHNU. La population d’étude était constituée des asthmatiques reçus en consultation. Les paramètres analysés concernent les caractéristiques de la population étudiée (âge, sexe, profession et statut matrimonial). Au total 296 patients asthmatiques, soit 36,5% d’hommes contre 63,5% de femmes, ont été enregistrés avec un âge médian qui était de 35 ans. 234 répondants à la variable catégorie socioprofessionnelle, étaient composés de ménagères (24,8%), d’élèves et d’étudiants (20,1%), de commerçants (17,5%), de bureaucrates (6,8%), de personnel de santé (6%) et d’enseignants et de maîtres coraniques (3,8%). A cela s’ajoutait, des ouvriers (3,8%), des couturiers (3,4%), des coiffeurs (3%), des chauffeurs (2,6%), des agriculteurs et éleveurs (2,6%), des mécaniciens et garagistes (1,3%), des pêcheurs et marins (1,3%), des restaurateurs et restauratrices (1,3%) et d’autres (1,7%). Selon le statut matrimonial, 54,3% étaient des mariés, 42,7% de célibataires et 3% de divorcés. Parmi les 296 asthmatiques, 250 résidaient en milieu urbain dakarois. Les antécédents se résumaient sur les signes et les symptômes des patients avec de la toux (34%), de la dyspnée expiratoire nocturne (34%), des expectorations nummulaires (18%) et des crises d’asthme (14%). Le profil des patients asthmatiques présente une population jeune avec une prédominance féminine. In Senegal, the prevalence of asthma has not yet been assessed. The socio-demographic, epidemiological and provenance characteristics of asthmatic patients consulted at the National Hospital University Center (CHNU) remain little known. This article contributes to the knowledge of the profile of asthmatic patients admitted to the CHNU. This was a retrospective, prospective and cross-sectional, analytical wise study combining the quantitative and qualitative approach which took place from January 1999 to august 2017 at the CHNU pulmonology clinic. The study of asthmatics received in consultation. The parameters analyzed relate to the characteristics of the population studied (age, sex, profession and marital status). A total of 296 asthmatic patients, or 36.5% male versus 63.5% female, were registered with a median age of 35 years. 234 respondents to the socio-professional category variable, were made up of housewives (24.8%), pupils and students (20.1%), traders (17.5%), bureaucrats (6.8%), health personnel (6%) and koranic teachers and teachers (3.8%). In addition, workers (3.8%), dressmakers (3.4%), hairdressers (3%), drivers (2.6%), farmers and ranchers (2.6%), mechanics and mechanics (1.3%), fishermen and sailors (1.3%), restaurateurs and restorers (1.3%), and others (1.7%). According to marital status, 54.3% were married, 42.7% were single and 3% were divorced. Among the 296 asthmatics, 250 resided in an urban Dakar environment. The history was summarized by the signs and symptoms of patients with cough (34%), nocturnal expiratory dyspnea (34%), sputum (18%) and asthma attacks (14%). The profile of asthmatic patients presents a young population with a female predominance

Influence of Growth Regulators on Callogenesis and Somatic Embryo Development in Date Palm (Phoenix dactylifera L.) Sahelian Cultivars

This study provides a physiological analysis of somatic embryogenesis in four elite cultivars of date palms: Ahmar, Amsekhsi, Tijib, and Amaside, from the initial callogenesis to establishment and proliferation of embryogenic suspension cultures. Somatic embryos development and in vitro plants rooting were also studied. For each step, auxins and cytokinins concentrations were optimised. The primary callogenesis from leaf explants of seedlings appeared highly dependent on genotype. Ahmar (80%) and Amsekhsi (76%) appeared highly callogenic, whereas Tijib (10%) and Amaside (2%) produced low amounts of calluses. 2,4-Dichlorophenoxyacetic acid appeared favorable to the induction of primary callogenesis and its effect was enhanced by the addition of benzyl adenine or adenine sulfate. Secondary friable calli obtained from chopped granular calli were used to initiate embryogenic cell suspensions in media supplied with 2,4-dichlorophenoxyacetic acid. Suspension cultures showed a growth rate of fourfold after four subcultures in presence of 2,4-dichlorophenoxyacetic acid 2 mg/L. Our results showed that a seven-day transitory treatment with benzyl adenine 0,5 mg/L was necessary to optimize embryos development. Naphthalene acetic acid induced the development of primary orthogravitropic roots during embryos germination. The comparison with cytofluorometry of nuclear DNA amounts showed no significant difference in ploidy level between regenerated plants and seedlings

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

BACKGROUND: rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa. METHODS: We did an open-label, cluster-randomised ring vaccination trial (Ebola ça Suffit!) in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone. We assessed the efficacy of a single intramuscular dose of rVSV-ZEBOV (2×107 plaque-forming units administered in the deltoid muscle) in the prevention of laboratory confirmed Ebola virus disease. After confirmation of a case of Ebola virus disease, we definitively enumerated on a list a ring (cluster) of all their contacts and contacts of contacts including named contacts and contacts of contacts who were absent at the time of the trial team visit. The list was archived, then we randomly assigned clusters (1:1) to either immediate vaccination or delayed vaccination (21 days later) of all eligible individuals (eg, those aged ≥18 years and not pregnant, breastfeeding, or severely ill). An independent statistician generated the assignment sequence using block randomisation with randomly varying blocks, stratified by location (urban vs rural) and size of rings (≤20 individuals vs >20 individuals). Ebola response teams and laboratory workers were unaware of assignments. After a recommendation by an independent data and safety monitoring board, randomisation was stopped and immediate vaccination was also offered to children aged 6-17 years and all identified rings. The prespecified primary outcome was a laboratory confirmed case of Ebola virus disease with onset 10 days or more from randomisation. The primary analysis compared the incidence of Ebola virus disease in eligible and vaccinated individuals assigned to immediate vaccination versus eligible contacts and contacts of contacts assigned to delayed vaccination. This trial is registered with the Pan African Clinical Trials Registry, number PACTR201503001057193. FINDINGS: In the randomised part of the trial we identified 4539 contacts and contacts of contacts in 51 clusters randomly assigned to immediate vaccination (of whom 3232 were eligible, 2151 consented, and 2119 were immediately vaccinated) and 4557 contacts and contacts of contacts in 47 clusters randomly assigned to delayed vaccination (of whom 3096 were eligible, 2539 consented, and 2041 were vaccinated 21 days after randomisation). No cases of Ebola virus disease occurred 10 days or more after randomisation among randomly assigned contacts and contacts of contacts vaccinated in immediate clusters versus 16 cases (7 clusters affected) among all eligible individuals in delayed clusters. Vaccine efficacy was 100% (95% CI 68·9-100·0, p=0·0045), and the calculated intraclass correlation coefficient was 0·035. Additionally, we defined 19 non-randomised clusters in which we enumerated 2745 contacts and contacts of contacts, 2006 of whom were eligible and 1677 were immediately vaccinated, including 194 children. The evidence from all 117 clusters showed that no cases of Ebola virus disease occurred 10 days or more after randomisation among all immediately vaccinated contacts and contacts of contacts versus 23 cases (11 clusters affected) among all eligible contacts and contacts of contacts in delayed plus all eligible contacts and contacts of contacts never vaccinated in immediate clusters. The estimated vaccine efficacy here was 100% (95% CI 79·3-100·0, p=0·0033). 52% of contacts and contacts of contacts assigned to immediate vaccination and in non-randomised clusters received the vaccine immediately; vaccination protected both vaccinated and unvaccinated people in those clusters. 5837 individuals in total received the vaccine (5643 adults and 194 children), and all vaccinees were followed up for 84 days. 3149 (53·9%) of 5837 individuals reported at least one adverse event in the 14 days after vaccination; these were typically mild (87·5% of all 7211 adverse events). Headache (1832 [25·4%]), fatigue (1361 [18·9%]), and muscle pain (942 [13·1%]) were the most commonly reported adverse events in this period across all age groups. 80 serious adverse events were identified, of which two were judged to be related to vaccination (one febrile reaction and one anaphylaxis) and one possibly related (influenza-like illness); all three recovered without sequelae. INTERPRETATION: The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters. FUNDING: WHO, UK Wellcome Trust, the UK Government through the Department of International Development, Médecins Sans Frontières, Norwegian Ministry of Foreign Affairs (through the Research Council of Norway's GLOBVAC programme), and the Canadian Government (through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development)

Ethno Apicultural Survey of Melliferous Plant Species in the Great Green Wall Widou and Koyli Alpha, Senegal

Dispositif de recherche interdisciplinaire sur les Interactions Hommes-Milieu

Data management of clinical trials during an outbreak of Ebola virus disease.

INTRODUCTION Clinical trial data management (DM) conducted during outbreaks like that of Ebola virus disease (EVD) in West Africa, 2014-2016, has to adapt to specific, unique circumstances. CTU Bern was asked to set up a safe data capture/management system that could be launched within a few weeks and cover two different vaccine trials. This article describes some of the challenges we faced and our solutions during the two different trials. METHODS Setting up a DM system was split into four phases/tasks: (1) quick set-up of the (electronic) data capture system (EDC) and mobile infrastructure in Bern, (2) moving the EDC and infrastructure to Conakry, Guinea and implementation of a local data management centre (DMC), (3) running the DMC, and (4) data cleaning. The DMC had to meet the following criteria: (1) quick implementation, (2) efficient maintenance and handling of data, and (3) procedures to guarantee data quality. The EDC (REDCap) was setup as a local area network. In order to ensure high data quality, double data entry, and then review of inconsistencies and offline plausibility checks were implemented. RESULTS From the start of CTU Bern's involvement to the productive EDC took 11 weeks. It was necessary to adapt processes for dealing with data continuously throughout the trial conduct phase. The data management team processed 171,794 case report form pages from a total of 14,203 participants in the period between March and December 2015. CONCLUSION Data management is a key task supporting trial conduct. For trials in emergency situations, many of our approaches are suitable, but we also provide a list of aspects that might be done differently

Quantitative Polymerase Chain Reaction from Malaria Rapid Diagnostic Tests to Detect Borrelia crocidurae, the Agent of Tick-Borne Relapsing Fever, in Febrile Patients in Senegal

International audienceABSTRACT. In endemic malaria areas, Plasmodium is currently diagnosed mainly through the use of rapid diagnostic tests (RDTs). However, in Senegal, many causes of fever remain unknown. Tick-borne relapsing fever, an often-neglected public health problem, is the main cause of consultation for acute febrile illness after malaria and flu in rural areas. Our objective was to test the feasibility of extracting and amplifying DNA fragments by quantitative polymerase chain reaction (qPCR) from malaria-negative RDTs for Plasmodium falciparum (malaria Neg RDTs P.f ) to detect Borrelia spp. and other bacteria. Between January and December 2019, malaria Neg RDTs P.f were collected on a quarterly basis in 12 health facilities in four regions of Senegal. The DNA extracted from the malaria Neg RDTs P.f was tested using qPCR and the results were confirmed by standard PCR and sequencing. Only Borrelia crocidurae DNA was detected in 7.22% (159/2,202) of RDTs. The prevalence of B. crocidurae DNA was higher in July (16.47%, 43/261) and August (11.21%, 50/446). The annual prevalence was 9.2% (47/512) and 5.0% (12/241) in Ngayokhem and Nema-Nding, respectively, health facilities in the Fatick region. Our study confirms that B. crocidurae infection is a frequent cause of fever in Senegal, with a high prevalence of cases in health facilities in the regions of Fatick and Kaffrine. Malaria Neg RDTs P.f are potentially a good source of pathogen sampling for the molecular identification of other causes of fever of unknown origin, even in the most remote areas